In the treatment of prostate cancer with oxaliplatin, the expression of CXCL1, CXCL8 and CXCR2 were significantly increased, while CXCR2 inhibitors could enhance the cytotoxicity of oxaliplatin and achieve the combined anti-tumor effect [35]. Here, CXCL1 is linked to prostate carcinoma.